Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
For those of you who read the blog here and are not aware of what a "Carnival" is, it represents a collection of some of the top blogging posts in a period of time assembled in one place to review and read. Today, Highlight Health is hosting the carnival and I am delighted that...
In a related story about the Broad Institute, this was released today: potential news and warnings of tumors that could become resistant to a common cancer drug when used upon a recurrence of a tumor. There's a lot going on with genomic research at the center and this is just one...
Genetic markers making their way to electronic medical records with locating potential patients through medical records to perhaps identify candidates that would benefit. Cerner is one of the larger software companies used by many hospitals in the US. A genetic test that would allow identification...
I get a kick out of stories like this, although there could be something to it. If the man has RS3 334, then toss him out it appears and the more copies the worse! But let's not leave this little factor just up to the male species, there's females out there too with issues. ...
This lends itself to an area whereby various area of cancer could be targeted, and with few or little side effect as the study states. The term "cellular immortality" is the term that describes cells that keep regenerating endlessly, like cancer cells do. It's a long way to...
Is Biotech risky business? I think we can all agree due to the research and development and the unknown areas as far as predicting a winner can be close to a roll of the dice at times. The bar has risen a bit today to secure VC funds no doubt and then we still hear about the failed trials...
This is an article written by Misha Angrist is an assistant professor at the Duke University Institute for Genome Sciences and discusses what do we do with our genome once we get it? Actually the article talks about where we are today with the technology. The only thing I think that we all...
This is hot stuff! Recently I had an in depth interview with Dr. Patrice Milos, Chief Scientific Officer at Helicos discussing genomics and where the future is going. Helicos has the software and the genomics machine, and wouldn't this be a nice addition to run on Surface. This...
Progress is being made and appears both sides are satisfied here. DeCode has also applied for a license. Both companies appear to be using a physician for the test results which was at the crux of the matter. We also need more physicians who understand genomics too, and recently DeCode...